Exagen(XGN) - 2024 Q2 - Quarterly Results

Exagen Inc. Reports Strong Second Quarter 2024 Results: Raises Guidance due to Record Performance August 5, 2024 Carlsbad, Calif., – Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2024. Highlights: • Recognized record total revenue of $15.1 million in the second quarter of 2024. • Delivered gross margin of 60.1% in the second quarter of 2024, compared to a gross margin of 58.7% in the second quarter of 2023. • AV ...